Corvus Pharmaceuticals Statistics
 Total Valuation
 CRVS has a market cap or net worth of $556.62 million. The enterprise value is $498.94 million.
   Important Dates
 The next confirmed earnings date is Tuesday, November 4, 2025, after market close.
 | Earnings Date  | Nov 4, 2025 | 
| Ex-Dividend Date  | n/a | 
  Share Statistics
 CRVS has 74.51 million shares outstanding. The number of shares has increased by 37.88% in one year.
 | Current Share Class  | 74.51M | 
| Shares Outstanding  | 74.51M | 
| Shares Change (YoY)  | +37.88% | 
| Shares Change (QoQ)  | +3.49% | 
| Owned by Insiders (%)  | 3.96% | 
| Owned by Institutions (%)  | 36.99% | 
| Float  | 57.36M | 
   Valuation Ratios
  | PE Ratio  | n/a | 
| Forward PE  | n/a | 
| PS Ratio  | n/a | 
| Forward PS  | n/a | 
| PB Ratio  | 7.13 | 
| P/TBV Ratio  | 7.13 | 
| P/FCF Ratio  | n/a | 
| P/OCF Ratio  | n/a | 
| PEG Ratio  | n/a | 
 Financial Ratio History  Enterprise Valuation
  | EV / Earnings  | n/a | 
| EV / Sales  | n/a | 
| EV / EBITDA  | n/a | 
| EV / EBIT  | n/a | 
| EV / FCF  | n/a | 
  Financial Position
 The company has a current ratio of 8.91, with a Debt / Equity ratio of 0.01.
 | Current Ratio  | 8.91 | 
| Quick Ratio  | 8.78 | 
| Debt / Equity  | 0.01 | 
| Debt / EBITDA  | n/a | 
| Debt / FCF  | n/a | 
| Interest Coverage  | n/a | 
   Financial Efficiency
 Return on equity (ROE) is -68.67% and return on invested capital (ROIC) is -33.34%.
 | Return on Equity (ROE)  | -68.67% | 
| Return on Assets (ROA)  | -28.84% | 
| Return on Invested Capital (ROIC)  | -33.34% | 
| Return on Capital Employed (ROCE)  | -43.90% | 
| Revenue Per Employee  | n/a | 
| Profits Per Employee  | -$1.46M | 
| Employee Count | 31 | 
| Asset Turnover  | n/a | 
| Inventory Turnover  | n/a | 
  Taxes
  | Income Tax  | n/a | 
| Effective Tax Rate  | n/a | 
  Stock Price Statistics
 The stock price has decreased by -15.60% in the last 52 weeks. The beta is 0.57, so CRVS's price volatility has been lower than the market average.
 | Beta (5Y)  | 0.57 | 
| 52-Week Price Change  | -15.60% | 
| 50-Day Moving Average  | 6.67 | 
| 200-Day Moving Average  | 4.79 | 
| Relative Strength Index (RSI)  | 57.46 | 
| Average Volume (20 Days)  | 1,093,318 | 
  Short Selling Information
 The latest short interest is 8.83 million, so 11.85% of the outstanding shares have been sold short.
 | Short Interest  | 8.83M | 
| Short Previous Month  | 10.10M | 
| Short % of Shares Out  | 11.85% | 
| Short % of Float  | 15.40% | 
| Short Ratio (days to cover)  | 9.25 | 
  Income Statement
  | Revenue  | n/a | 
| Gross Profit  | n/a | 
| Operating Income  | -35.54M | 
| Pretax Income  | -45.14M | 
| Net Income  | -45.14M | 
| EBITDA  | -35.45M | 
| EBIT  | -35.54M | 
| Earnings Per Share (EPS)  | -$1.02 | 
 Full Income Statement  Balance Sheet
 The company has $74.41 million in cash and $1.08 million in debt, giving a net cash position of $73.32 million or $0.98 per share.
 | Cash & Cash Equivalents  | 74.41M | 
| Total Debt  | 1.08M | 
| Net Cash  | 73.32M | 
| Net Cash Per Share  | $0.98 | 
| Equity (Book Value)  | 80.23M | 
| Book Value Per Share  | 1.08 | 
| Working Capital  | 67.28M | 
 Full Balance Sheet  Cash Flow
 In the last 12 months, operating cash flow was -$28.83 million and capital expenditures -$149,000, giving a free cash flow of -$28.98 million.
 | Operating Cash Flow  | -28.83M | 
| Capital Expenditures  | -149,000 | 
| Free Cash Flow  | -28.98M | 
| FCF Per Share  | -$0.39 | 
 Full Cash Flow Statement  Margins
  | Gross Margin  | n/a | 
| Operating Margin  | n/a | 
| Pretax Margin  | n/a | 
| Profit Margin  | n/a | 
| EBITDA Margin  | n/a | 
| EBIT Margin  | n/a | 
| FCF Margin  | n/a | 
  Dividends & Yields
 CRVS does not appear to pay any dividends at this time.
 | Dividend Per Share  | n/a | 
| Dividend Yield  | n/a | 
| Dividend Growth (YoY)  | n/a | 
| Years of Dividend Growth  | n/a | 
| Payout Ratio  | n/a | 
| Buyback Yield  | -37.88% | 
| Shareholder Yield  | -37.88% | 
| Earnings Yield  | -7.89% | 
| FCF Yield  | -5.06% | 
    Analyst Forecast
 The average price target for CRVS is $13.75, which is 84.07% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target  | $13.75 | 
| Price Target Difference  | 84.07% | 
| Analyst Consensus  | Strong Buy | 
| Analyst Count  | 4 | 
| Revenue Growth Forecast (5Y)  | n/a | 
| EPS Growth Forecast (5Y)  | n/a | 
 Stock Forecasts  Fair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value  | n/a | 
| Lynch Upside  | n/a | 
| Graham Number  | n/a | 
| Graham Upside  | n/a | 
  Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date  | n/a | 
| Split Type  | n/a | 
| Split Ratio  | n/a | 
  Scores
  | Altman Z-Score  | n/a | 
| Piotroski F-Score  | 2 |